hIL17A/hIL17F

Fig1. Analysis of IL17F gene expression in the kidney by RT-PCR. Mouse Il17f mRNA was detectable by P1/2(440bp), human IL17F mRNA was detectable by P3/4(259bp), M:100bp Plus DNA ladder from Transgen (BM311). The heterozygous KI mice express both human IL17F and mouse Il17f in the kidney.

Fig2. Analysis of IL17A gene expression in the spleen by RT-PCR in WT and IL17A/IL17F humanized mice . Mouse Il17a mRNA was detectable by P1/2(490bp), human IL17A mRNA was detectable by P3/4(443bp), M:100bp Plus DNA ladder from Transgen (BM311). The heterozygous KI mouse expresses both human IL17A and mouse Il17a in the spleen.

Fig3. Detection of hIL17A expression in serum(A), spleen homogenate(B) and thymus homogenate(C) by ELISA (6 wks, male, n=3). 

Abbr. HO, homozygous; WT, wild type. Note. hIL17A/hIL17F and C57BL/6 mice were i.p. injected with LPS.

Fig4. Detection of hIL17F expression in serum(A), spleen homogenate(B) and thymus homogenate(C) by ELISA  (6 wks, male, n=3). 

Abbr. HO, homozygous; WT, wild type. Note. hIL17A/hIL17F and C57BL/6 mice were i.p. injected with LPS.

Fig.5 IMQ induced Psoriasis model in HO/HO hIL17A/hIL17F mice. 

After 7 days of induction, serum was collected and hIL17A expression was detected by ELISA.

Fig6. Body weight (A) and body weight change (B) of IMQ induced Psoriasis model in hIL17A/hIL17F mice. (n=6).

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig7. IMQ induced Psoriasis model in hIL17A/hIL17F mice.(A) ear thickness (B) skin thickness (C) clinical score (n=6). 

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig8. IMQ induced Psoriasis model in hIL17A/hIL17F mice (A) erythema score (B) skin thickness score (C) scabby score (n=6).

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig.9 IMQ induced Psoriasis model in hIL17A/hIL17F mice. 

At the study endpoint, back skin samples were harvested and stained with H&E. Representative H&E staining images of the back skin from mice and histological changes were quantified using Baker system.  Results indicated that Bimekizumab significantly reduced skin lesions in IMQ induced Psoriasis model in hIL17A/hIL17F mice (n=6). Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, ***P < 0.001.

Fig.10 IMQ induced Psoriasis model in hIL17A/hIL17F mice. 

At the study endpoint, back skin samples were harvested and hIL17F was tested by qPCR. Results indicated that Bimekizumab significantly reduced hIL17F expression level in IMQ induced Psoriasis model in hIL17A/hIL17F mice(n=6). Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05.